Home Cart 0 Sign in  
X

[ CAS No. 6164-79-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 6164-79-0
Chemical Structure| 6164-79-0
Chemical Structure| 6164-79-0
Structure of 6164-79-0 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 6164-79-0 ]

Related Doc. of [ 6164-79-0 ]

Alternatived Products of [ 6164-79-0 ]

Product Details of [ 6164-79-0 ]

CAS No. :6164-79-0 MDL No. :MFCD00014611
Formula : C6H6N2O2 Boiling Point : -
Linear Structure Formula :- InChI Key :TWIIRMSFZNYMQE-UHFFFAOYSA-N
M.W : 138.12 Pubchem ID :72662
Synonyms :

Calculated chemistry of [ 6164-79-0 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 2
Num. H-bond acceptors : 4.0
Num. H-bond donors : 0.0
Molar Refractivity : 33.31
TPSA : 52.08 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.31 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.14
Log Po/w (XLOGP3) : -0.23
Log Po/w (WLOGP) : 0.26
Log Po/w (MLOGP) : -0.88
Log Po/w (SILICOS-IT) : 0.72
Consensus Log Po/w : 0.2

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.86
Solubility : 18.9 mg/ml ; 0.137 mol/l
Class : Very soluble
Log S (Ali) : -0.41
Solubility : 54.2 mg/ml ; 0.392 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -1.7
Solubility : 2.76 mg/ml ; 0.02 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.68

Safety of [ 6164-79-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 6164-79-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 6164-79-0 ]
  • Downstream synthetic route of [ 6164-79-0 ]

[ 6164-79-0 ] Synthesis Path-Upstream   1~24

  • 1
  • [ 6164-79-0 ]
  • [ 6705-33-5 ]
YieldReaction ConditionsOperation in experiment
80%
Stage #1: With sodium tetrahydroborate In water for 0.5 h;
Stage #2: With water; potassium carbonate In ethanol for 0.5 h;
The 4- (3-CHLORO-4- (2-PYAZINYLMETHOXY) anilino) -5-fluoroquinazoline used as starting material was obtained as follows: Methylpyrazine carboxylate (8.5g) was stirred in water (200 ml) and sodium borohydride (11.65 g) was added in one portion, resulting in a vigorous exotherm. The reaction mixture was stirred vigorously for 30 minutes, and then ethanol (80 ML) and saturated potassium carbonate (150 ml) were added. The mixture was stirred for 30 minutes and then extracted with ethyl acetate (5 x 150 ml) and DCM (5 x 150 ml). The combined extracts were dried and concentrated to give pyrazin-2-ylmethanol as a yellow oil (5.43 g, 80percent), which was used without purification; NMR spectrum (DMSO-D6) 4.65 (s, 2H), 5.57 (br s, 1H), 8.54 (d, 2H), 8.71 (s, 1H).
75% With sodium tetrahydroborate; calcium chloride In ethanol at 25℃; for 5 h; To methyl pyrazine-2-carboxylate (3.35 g, 24.3 mmol) in EtOH (60 mL) was added calcium chloride (4.03 g, 36.4 mmol) followed by sodium borohydride (1.38 g, 36.4 mmol). The reaction mixture was stirred at 23°C for 5 h. The mixture was quenched with a mixture of acetic acid (4.20 mL, 72.8 mmol) and water (1.31 mL, 72.8 mmol), and stirred for 30 min. The mixture was filtered through a pad a silica gel, and the pad was washed with 5-10percent MeOH/DCM containing 0.3percent conc. NH3 (aq). The combined filtrates were concentrated in vacuo, and the crude residue was purified by FCC (SiO2, elution with 0-10percent MeOH/DCM)to provide 2.01 g (75percent) of pyrazin-2-ylmethanol. 1H NMR (400 MHz, d6-DMSO): d ppm 8.71 (m, 1H), 8.56 (dd, 1H), 8.54 (d, 1H), 5.61 (t, 1H), 4.63 (d, 2H); LCMS (Method E): tR= 0.56 min, m/z 111.3 (M+H)+. Step 3: 2-(Chloromethyl)pyrazine
36%
Stage #1: With lithium aluminium tetrahydride In tetrahydrofuran at 0℃; for 0.25 h; Inert atmosphere
Stage #2: With sodium hydroxide In tetrahydrofuran; water at 20℃; for 1 h;
Step 2; Lithium aluminum hydride (40.0 mg, 1.06 mmol) was suspended in tetrahydrofuran (1.0 mL). To this, a solution of methyl 2-pyrazinecarboxylate (66.0 mg, 0.478 mmol) in tetrahydrofuran (0.5 mL) was added dropwise under a nitrogen atmosphere at 0° C. and the mixture was stirred at the same temperature for 15 minutes. Then, water (40 μL), a 15percent aqueous sodium hydroxide solution (40 μL) and water (120 μL) were successively added to the reaction mixture and the mixture was stirred at room temperature for 1 hour. The mixture was filtered through Celite and the mother liquid was concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol=9/1) to give 2-pyrazinemethanol (Compound CD) (19.0 yield: 36percent).1H-NMR (270 MHz, CDCl3, δ): 3.11 (brd, J=5.6 Hz, 1H), 4.85 (d, J=5.6 Hz, 1H), 8.52-8.55 (m, 2H), 8.64 (s, 1H).
0.3 g
Stage #1: at 0 - 20℃; Inert atmosphere
Stage #2: at 20℃; for 1 h; Inert atmosphere
[0537] Synthesis of pyrazin-2-ylmethanol: [0538] To a stirred solution of methyl pyrazine-2-carboxylate (0.5 g, 3.62 mmol) in H20 (10 mL) was added NaBH4 (685 g, 18.02 mmol) portion wise at 0 °C, and the reaction mixture was allowed to warm to RT and stirred for 30 min under inert atmosphere. To this saturated K2C03 (10 mL) and EtOH (5 mL) was added and stirring was continued for another 1 h at RT. The progress of the reaction was monitored by TLC; the reaction mixture was extracted with EtOAc. The combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to afford crude pyrazin-2-ylmethanol (0.3 g). LC-MS: 99.91percent; 111.9 (M++l) (column; X-bridge C-18, (50x3.0 mm, 3.5μ); RT 0.72 min. 0.1percent TFA in water: ACN; 0.8 ml/min); TLC: 100percent EtOAc (Rf: 0.2).

Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 3, p. 1431 - 1440
[2] Patent: WO2004/93880, 2004, A1, . Location in patent: Page/Page column 86
[3] Patent: WO2017/214359, 2017, A1, . Location in patent: Page/Page column 73
[4] Synthetic Communications, 2005, vol. 35, # 24, p. 3187 - 3190
[5] Patent: US2011/237584, 2011, A1, . Location in patent: Page/Page column 132
[6] Bulletin des Societes Chimiques Belges, 1982, vol. 91, # 2, p. 153 - 162
[7] Molecules, 2009, vol. 14, # 10, p. 4197 - 4212
[8] Patent: WO2012/40230, 2012, A1, . Location in patent: Page/Page column 90
[9] Patent: WO2013/142269, 2013, A1, . Location in patent: Paragraph 0537; 0538
[10] Journal of the American Chemical Society, 2014, vol. 136, # 23, p. 8350 - 8360
[11] Patent: WO2017/156181, 2017, A1, . Location in patent: Paragraph 00340
[12] Supramolecular Chemistry, 2018, vol. 30, # 4, p. 296 - 304
  • 2
  • [ 6164-79-0 ]
  • [ 144-55-8 ]
  • [ 87-69-4 ]
  • [ 6705-33-5 ]
Reference: [1] Patent: US6255305, 2001, B1,
  • 3
  • [ 6164-79-0 ]
  • [ 98-96-4 ]
Reference: [1] Journal of the American Chemical Society, 1940, vol. 62, p. 664
[2] Yakugaku Zasshi, 1956, vol. 76, p. 470[3] Chem.Abstr., 1956, p. 14777
[4] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 22, p. 622
[5] Journal of Chemical Thermodynamics, 2005, vol. 37, # 1, p. 49 - 53
  • 4
  • [ 67-56-1 ]
  • [ 98-97-5 ]
  • [ 6164-79-0 ]
YieldReaction ConditionsOperation in experiment
98% for 2 h; Reflux Pyrazine-2-carboxylic acid (5 g, 40.3 mmol) was dissolved inMeOH (150 ml), and a few drops of H2SO4 were added. The resultingreaction mixture was refluxed for 2 h. Methanol was evaporated and the resulting reaction mixture was extracted withEtOAc, washed with saturated NaHCO3 solution, then with brineand dried over anhydrous Na2SO4. The solvent was removed invacuo to give the methyl pyrazine-2-carboxylate (5.5 g, yield98percent). 1H NMR (CDCl3, 400 MHz) d 9.32 (d, 1H, J = 1.5 Hz), 8.78(d, 1H, J = 2.4 Hz), 8.73 (dd, 1H, J = 2.4, 1.5 Hz), 4.04 (s, 3H).
94.8% at 80 - 85℃; for 5 h; Example 1; Methyl pyrazine-2-carboxylate (Formula 3). 20.0 g (805.8 mmole) of pyrazine-2-carboxylic acid was added to 160 mL of methanol, and 1.0 mL of a concentrated sulfuric acid was gradually dropwise added thereto with stirring. A reaction solution was refluxed at a temperature of 80 to 85°C for 5 hours. The reaction solution was cooled to a temperature of 20 to 22 °C and concentrated to a volume of 25mL. Then, 80 mL of methylenechloride and 40 mL of water were added to the resultant concentrate. The resultant solution was then neutralized by gradual addition of 40 mL of a saturated sodium hydrogen carbonate solution to get a pH of 8.5. An organic layer was separated and a water layer was extracted again with 40 mL of methylenechloride. The combined organic layer was dried over anhydrous magnesium sulfate, filtered, and washed with 20 mL of methylenechloride. A filtrate was concentrated to give 21.1 g of the titled compound as a pale brown solid (yield 94.8percent). Melting point: 60-61 °C
91% at 55 - 65℃; for 19 h; Industrial scale • Charged MeOH (8.8 L) and OT-1 (1758 g) at RT. (0129) • Charged H2S04 (69.5 g) in one portion (21-22 °C exotherm). Heated to (60-65 °C) and stirred at 55-65 °C for 19 hours. (0130) 19 h, 96.0percent OT-2 and 4.0percent OT-1 by HPLC (0131) • Reaction was cooled to 15/30 °C. No precipitate formed. (0132) • NaHC03 (180 g) was charged in lots. The solution bubbled slightly and quickly went from yellow to pink. The mixture was stirred for 5 min at 15/30 °C. (0133) • The mixture was then concentrated to 1.5-2.5 vol at (0134) • Charged NaCl (.700 g) in water (2.5 vol). Upon stirring, solution became clear. (0135) • Stirred for 15 min at 15/30 °C. After stirring, the aqueous layer became slightly cloudy. The solids were filtered off and the layers were separated. (0136) • The aqueous layer was extracted with DCM (3x2 vol.). TLC indicated that extraction was complete after 3rd extraction. (0137) • Organic layers were dried over anhydrous Na2S04 (.4g/g SM) . (0138) • Concentrated to 1.5-2.5 vol under vacuum at (0139) • Charged heptanes (8 vol) over a minimum of 30 min. Pale white slurry. Let stir overnight. • Stirred at -5/- 15 °C for a minimum of 1 hr. Solids were filtered off and rinsed with cold heptanes (0140) • (2x1 vol.) Pulled solids dry on filter for 10 min. Dried in vacuum oven at (0141) Color changed, but no degradation was observed . (0142) Output material: ST-601 (0143) Lot No.: 2463-24- 1 (0144) Appearance: light Brown Solids (0145) Yield: 1721 g (91.0percent) (0146) HPLC purity: 98.9percent (0147) 1 NMR- Conforms to structure
87%
Stage #1: at -10℃; for 0.5 h; Inert atmosphere
Stage #2: at 20℃; for 72 h;
Stage #3: With sodium hydrogencarbonate In water
REFERENCE EXAMPLE 8-42-pyrazinemethanol (Compound CD)Step 1; To methanol (8.0 mL), thionyl chloride (2.08 mL) was added dropwise under a nitrogen atmosphere at -10° C. and the mixture was stirred at the same temperature for 30 minutes. To this, 2-pyrazinecarboxylic acid (1.00 g, 8.06 mmol) was added at the same temperature and the mixture was stirred at room temperature for 72 hours. The reaction mixture was concentrated, a saturated aqueous sodium bicarbonate solution was added to the residue, and extraction with ethyl acetate was performed, followed by washing with brine and drying over anhydrous sodium sulfate. The solvent was evaporated off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform/methanol 19/1) to give methyl 2-pyrazinecarboxylate (969 mg, yield: 87percent).1H-NMR (270 MHz, CDCl3, δ); 4.06 (s, 3H), 8.74 (dd, J=1.3, 2.3 Hz, 1H), 8.79 (d, J=1.3 Hz, 1H), 9.34 (d, J=2.3 Hz, 1H).
72% for 6 h; Reflux General procedure: A catalytic amount of concentrated H2SO4 wasadded to a solution of carboxylic acids 16(a–j) (1.0 mmol)in 50 mL of methanol, and the mixture was refluxed for 6 h. It was allowed to cool. The saturated solution ofNaHCO3 was added to the reaction mixture, and it wasextracted with EtOAc (2 X 50 mL). The combined organiclayer was dried Na2SO4 and concentrated to obtain puremethyl esters 17(a–j).
63.63% for 5 h; Reflux [0535] Synthesis of methyl pyrazine-2-carboxylate: [0536] To a stirred solution of pyrazine-2-carboxylic acid (5 g, 40.29 mmol) in MeOH (20 mL) was added concentrated H2S04 (1 mL) drop-wise and stirred under reflux for 5 h. The reaction mixture was cooled to RT; volatiles were evaporated under reduced pressure. The residue was diluted with water and basified to pH~ 8.5 using NaHC03 and extracted with EtOAc. Combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to afford methyl pyrazine-2- carboxylate (3.5 g, 63.63percent) as an off-white solid. 1H-NMR (DMSO d6, 400 MHz): δ 9.21 (s, 1H), 8.91 (d, 1H), 8.82 (d, 1H), 3.92 (s, 3H); TLC: 50percent EtOAc/Hexane (Rf: 0.4).
53%
Stage #1: With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 23℃; for 6 h;
Stage #2: for 0.5 h;
To pyrazinecarboxylic acid (5.80 g, 46.5 mmol) in dichloromethane (100 mL) was added oxalyl chloride (5.10 mL, 60.4 mmol) followed by catalytic DMF. The reaction mixture was stirred at 23°C for 6 h. Methanol (30 mL) was then added, and the mixture was stirred for an additional 30 min. The reaction mixture was concentrated in vacuo. The residue was taken up in EtOAc (200 mL), and washed with sat. NaHCO3 (aq) (1X100 mL) and brine (1X100mL). The organic layer was dried (MgSO4), and concentrated in vacuo to provide 3.38 g (53percent) of methyl pyrazine-2-carboxylate which was used without further purification in the next step.1H NMR (400 MHz, CDCl3): d ppm 9.34 (d, 1H), 8.79 (d, 1H), 8.74 (dd, 1H), 4.06 (s, 3H); LCMS (Method A): tR= 0.48 min, m/z 139.3 (M+H)+.

Reference: [1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 12, p. 2843 - 2851
[2] Journal of the American Chemical Society, 1990, vol. 112, # 17, p. 6248 - 6254
[3] Patent: WO2004/48369, 2004, A1, . Location in patent: Page 8
[4] Tetrahedron Letters, 2009, vol. 50, # 28, p. 4030 - 4032
[5] Patent: WO2016/207914, 2016, A2, . Location in patent: Page/Page column 3; 13; 14
[6] European Journal of Inorganic Chemistry, 2009, # 9, p. 1162 - 1171
[7] Patent: US2011/237584, 2011, A1, . Location in patent: Page/Page column 132
[8] European Journal of Pharmaceutical Sciences, 2014, vol. 53, # 1, p. 1 - 9
[9] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1983, vol. 22, # 5, p. 505
[10] European Journal of Medicinal Chemistry, 2009, vol. 44, # 12, p. 4954 - 4959
[11] Letters in Drug Design and Discovery, 2010, vol. 7, # 4, p. 275 - 280
[12] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[13] Chemical Communications, 2007, # 38, p. 3957 - 3959
[14] Patent: WO2013/142269, 2013, A1, . Location in patent: Paragraph 0535; 0536
[15] Patent: WO2017/214359, 2017, A1, . Location in patent: Page/Page column 72-73
[16] Zhurnal Obshchei Khimii, 1955, vol. 25, p. 2313,2314, 2315; engl. Ausg. S. 2285, 2286
[17] Journal of the American Chemical Society, 1940, vol. 62, p. 664
[18] Journal of the American Chemical Society, 1952, vol. 74, p. 1345
[19] Patent: CH187538, 1935, ,
[20] Zeitschrift fuer Naturforschung, B: Chemical Sciences, 1987, vol. 42, # 4, p. 425 - 430
[21] Journal of Chemical Thermodynamics, 2005, vol. 37, # 1, p. 49 - 53
[22] Patent: US2009/306096, 2009, A1, . Location in patent: Page/Page column 19
[23] Patent: WO2005/92304, 2005, A2, . Location in patent: Page/Page column 39
[24] Molecules, 2009, vol. 14, # 10, p. 4197 - 4212
[25] Magnetic Resonance in Chemistry, 2009, vol. 47, # 7, p. 617 - 624
[26] European Journal of Medicinal Chemistry, 2010, vol. 45, # 8, p. 3384 - 3388
[27] European Journal of Inorganic Chemistry, 2011, # 32, p. 5036 - 5042
[28] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 21, p. 6356 - 6365
[29] Journal of Heterocyclic Chemistry, 2012, vol. 49, # 6, p. 1317 - 1322
[30] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 90 - 95
[31] Dalton Transactions, 2017, vol. 46, # 30, p. 9875 - 9885
[32] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
  • 5
  • [ 98-97-5 ]
  • [ 6164-79-0 ]
YieldReaction ConditionsOperation in experiment
63.63%
Stage #1: With sulfuric acid In methanol at 20℃; for 5 h; Reflux
Stage #2: With sodium hydrogencarbonate In methanol
Synthesis of methyl pyrazine-2-carboxylate: To a stirred solution of pyrazine-2-carboxylic acid (5 g, 40.29 mmol) in MeOH (20 mL) was added concentrated H2S04 (1 mL) drop wise and stirred under reflux for 5 h. The reaction mixture was cooled to RT; volatiles were evaporated under reduced pressure. The residue was diluted with water and basified to pH~ 8.5 using NaHC03 and extracted with EtOAc. Combined organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to afford methyl pyrazine-2-carboxylate (3.5 g, 63.63percent) as an off- white solid. 1H-NMR (DMSO d6, 400 MHz): δ 9.21 (s, 1H), 8.91 (d, 1H), 8.82 (d, 1H), 3.92 (s, 3H); TLC: 50percent EtOAc/Hexane (Rf: 0.4).
Reference: [1] Patent: WO2012/40230, 2012, A1, . Location in patent: Page/Page column 89-90
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 20, p. 3902 - 3907
[3] Patent: US5945534, 1999, A,
[4] Patent: US2004/53989, 2004, A1,
  • 6
  • [ 290-37-9 ]
  • [ 600-23-7 ]
  • [ 6164-79-0 ]
Reference: [1] Tetrahedron Letters, 1992, vol. 33, # 21, p. 3057 - 3060
  • 7
  • [ 98-97-5 ]
  • [ 74-88-4 ]
  • [ 6164-79-0 ]
YieldReaction ConditionsOperation in experiment
8% With potassium carbonate In N,N-dimethyl-formamide for 72 h; Example 19.1Pyrazine-2-carboxylic acid methyl ester To pyrazine-2-carboxylic acid (15.0 g, 121 mmol) in DMF (150 mL) were added K2CO3 (50 g, 363 mmol) and MeI (9.0 mL, 145 mmol). After stirring for 3 days, the reaction mixture was filtered and then concentrated. The residue was dissolved in ethyl acetate, washed with water (3 times) and brine, dried over anhydrous Na2SO4, filtered and concentrated. Purification by flash column chromatography eluted with 10-30percent ethyl acetate in hexanes gave the title product (1.28 g, 8percent).1H NMR (300 MHz, CDCl3): δ (ppm) 9.35 (s, 1H), 8.80 (s, 1H), 8.75 (s, 1H), 4.07 (s, 3H).
Reference: [1] Patent: US2007/259862, 2007, A1, . Location in patent: Page/Page column 25-26
  • 8
  • [ 67-56-1 ]
  • [ 1254073-95-4 ]
  • [ 6164-79-0 ]
Reference: [1] Patent: WO2010/125102, 2010, A1, . Location in patent: Page/Page column 125
  • 9
  • [ 186581-53-3 ]
  • [ 98-97-5 ]
  • [ 6164-79-0 ]
Reference: [1] European Journal of Medicinal Chemistry, 2002, vol. 37, # 2, p. 163 - 170
  • 10
  • [ 14508-49-7 ]
  • [ 67-56-1 ]
  • [ 201230-82-2 ]
  • [ 6164-79-0 ]
Reference: [1] Organic Letters, 2004, vol. 6, # 13, p. 2097 - 2100
[2] Synthesis, 1990, vol. 1, # 10, p. 923 - 924
[3] Synthesis, 1990, vol. 1, # 10, p. 923 - 924
  • 11
  • [ 98-97-5 ]
  • [ 75-36-5 ]
  • [ 6164-79-0 ]
Reference: [1] Patent: US6297235, 2001, B1,
  • 12
  • [ 67-56-1 ]
  • [ 19847-10-0 ]
  • [ 6164-79-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1995, vol. 38, # 20, p. 3902 - 3907
  • 13
  • [ 89-01-0 ]
  • [ 6164-79-0 ]
Reference: [1] Journal of the American Chemical Society, 1940, vol. 62, p. 664
  • 14
  • [ 13925-00-3 ]
  • [ 6164-79-0 ]
Reference: [1] Journal of Chemical Thermodynamics, 2005, vol. 37, # 1, p. 49 - 53
  • 15
  • [ 73763-86-7 ]
  • [ 6164-79-0 ]
Reference: [1] Journal of the American Chemical Society, 1953, vol. 75, p. 679
[2] Yakugaku Zasshi, 1956, vol. 76, p. 470[3] Chem.Abstr., 1956, p. 14777
  • 16
  • [ 4744-50-7 ]
  • [ 6164-79-0 ]
Reference: [1] Journal of the American Chemical Society, 1953, vol. 75, p. 679
[2] Yakugaku Zasshi, 1956, vol. 76, p. 470[3] Chem.Abstr., 1956, p. 14777
  • 17
  • [ 6164-79-0 ]
  • [ 768-05-8 ]
YieldReaction ConditionsOperation in experiment
100% With hydrazine In ethanol for 2 h; Heating / reflux Pyrazine-2-carboxylic acid hydrazide. To a stirred solution of pyrazine-2-carboxylic acid methyl ester (11.1 g, 80 mmol) in 140 mL OF ETOH was added hydrazine hydrate (15.6 ML, 320 mmol). The resultant solution was heated to reflux for 2h. The solvent was removed under reduced pressure and dried under high vacuum to yield the title amide (11.1 g, 100percent) as a white solid. The product was used in subsequent steps without purification.
100% With hydrazine In ethanol for 2 h; Heating / reflux Example 261; 5-Phenyl-2-(3-pyrazin-2-yl-ureido)-thiophene-3-carboxylic acid (S)-azepan-3-ylamide pyrazine-2-carbohydrazide. ; To a stirred solution of methyl pyrazine-2-carboxylate (11.1 g, 80 mmol) in 140 mL of EtOH was added hydrazine hydrate (15.6 mL, 320 mmol). The resultant solution was heated to reflux for 2h. The solvent was removed under reduced pressure and dried under high vacuum to yield the title amide (11.1 g, 100percent) as a white solid. The product was used in subsequent steps without purification.'H NMR (d6-DMSO 8 10.1, br s, 1H; 8 9.12, d, 1H ; 8 8. 83, d, 1H ; 8 8.70, dd, 1H; 8 4.64, br s, 2H), LC/MS (APCI, ES, M+H=139).
75% With hydrazine hydrate In methanol for 5 h; Reflux General procedure: To a solution of an appropriate methyl esters17(a–j) (1.0 mmol) in 50 mL of methanol was added 99 percenthydrazine hydrate (4.0 mmol) and the mixture was refluxedfor 5 h up to reaction completed (TLC). After completionof reaction, it was allowed to cool and the obtained solidwas washed with methanol. The crude products wererecrystallized from ethanol.
68% at 78℃; Example 21.1Pyrazine-2-carbohydrazide To the title compound of Example 19.1 (1.28 mg, 9.3 mmol) in ethanol (10 mL) was added hydrazine hydrate (0.54 mL, 11.1 mmol) and then heated at 78° C. overnight. The reaction mixture was cooled and concentrated in vacuo. The residue was triturated with ethyl acetate, filtered and dried to give the title product as a yellow solid (870 mg, 68percent).1H NMR (300 MHz, (CD3)2SO): δ (ppm) 10.16 (broad s, 1H), 9.13 (s, 1H), 8.84 (s, 1H), 8.70 (s, 1H), 4.65 (broad s, 2H).
56% With hydrazine In tetrahydrofuran for 3 h; Reflux Methyl pyrazine-2-carboxylate (0.5g; 3.6mmol) was dissolved in THF (5mL), and 98percent hydrazine (0.53mL; 11mmol) was added. The mixture was refluxed for 3h and cooled to rt. The resulting solid was filtered off, washed with THF and dried over P2O5 to give 0.28g (56percent) of a white solid. Rf=0.53 (CHCl3/MeOH 10:1). mp 166–169°C (lit. 167–169°C) [64]. 1H NMR (300MHz, DMSO): δ 10.11 (s, 1H, NH), 9.12 (s, 1H, Ar), 8.82 (d, J=2.4Hz, 1H, Ar), 8.68 (d, J=2.4Hz, 1H, Ar), 4.65 (s, 2H, NH2). 13C NMR (75MHz, DMSO): δ 161.7, 147.4, 145.1, 143.7, 143.4.

Reference: [1] Patent: WO2005/16909, 2005, A1, . Location in patent: Page/Page column 73
[2] Patent: WO2005/66163, 2005, A2, . Location in patent: Page/Page column 128
[3] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 14, p. 5007 - 5015
[4] European Journal of Inorganic Chemistry, 2011, # 32, p. 5036 - 5042
[5] European Journal of Medicinal Chemistry, 2009, vol. 44, # 12, p. 4954 - 4959
[6] Letters in Drug Design and Discovery, 2010, vol. 7, # 4, p. 275 - 280
[7] Medicinal Chemistry, 2011, vol. 7, # 3, p. 245 - 249
[8] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[9] Patent: US2007/259862, 2007, A1, . Location in patent: Page/Page column 26
[10] Chemistry - A European Journal, 2018, vol. 24, # 39, p. 9928 - 9939
[11] Chemical Communications, 2012, vol. 48, # 5, p. 708 - 710
[12] Chemistry - A European Journal, 2012, vol. 18, # 2, p. 442 - 445
[13] European Journal of Medicinal Chemistry, 2016, vol. 120, p. 97 - 110
[14] Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 22, p. 622
[15] Patent: US2149279, 1935, ,
[16] Journal of Medicinal Chemistry, 1989, vol. 32, # 11, p. 2474 - 2485
[17] Patent: US6297235, 2001, B1,
[18] European Journal of Medicinal Chemistry, 2010, vol. 45, # 8, p. 3384 - 3388
[19] Patent: WO2010/125102, 2010, A1, . Location in patent: Page/Page column 125-126
[20] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 21, p. 6356 - 6365
[21] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 90 - 95
[22] Dalton Transactions, 2017, vol. 46, # 30, p. 9875 - 9885
[23] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
[24] Chemical Research in Toxicology, 2018, vol. 31, # 6, p. 435 - 446
[25] Patent: US2149279, 1935, ,
  • 18
  • [ 6164-79-0 ]
  • [ 27825-21-4 ]
  • [ 33332-25-1 ]
Reference: [1] Magnetic Resonance in Chemistry, 2009, vol. 47, # 7, p. 617 - 624
  • 19
  • [ 6164-79-0 ]
  • [ 5780-66-5 ]
YieldReaction ConditionsOperation in experiment
100%
Stage #1: With lithium aluminium tetrahydride In tetrahydrofuran at -78 - 72℃; for 0.333333 h;
Method 54; Pvrazine-2-carboxaldehyde oxime A IN solution of lithium aluminium hydride in THF (73. 8ml, 73.8mmol) was added to a suspension of methyl pyrazine-2-carboxylate (20g, 145mmol) in anhydrous THF (300. 0ml) at-78°C keeping the reaction temperature below-72°C. On completion of addition the reaction mixture was left to stir at-78°C for a further 20 minutes and then quenched with glacial acetic acid (20. 0ml). The resulting mixture was warmed to room temperature and the volatiles removed by evaporation. The residue was dissolved in 3N hydrochloric acid (116ml) and extracted with DCM. The extracts were combined, washed with saturated aqueous sodium hydrogen carbonate solution and the solvent evaporated. The residue was purified by chromatography on silica gel eluting with DCM/diethylether (100: 0 then 80: 20 and then 0: 100) to give pyrazine-2-carboxaldehyde (15.67g, 100percent). This was immediately dissolved in chloroform (200ml) cooled to 0°C and hydroxylamine mono-hydrochloride (11. 02g, 159. 5mmol) and triethylamine (24. 2ml, 117. 4mmol) were added. The reaction mixture was then stirred at ambient temperature for 0.5 hour, and the solvent removed by evaporation. The residue suspended in diethylether (500ml) and the insolubles removed by filtration. The filtrate was evaporated and the residue purified by chromatography eluting with DCM/diethylether (100: 0 then 80: 20 and then 0: 100) to give the title compound (5. 5g, 31percent) as a solid. NMR (DMSO-d6) : 8.15 (s, 1H), 8.62 (dd, 2H), 8. 99 (s, 1H).
Reference: [1] Patent: WO2005/40159, 2005, A1, . Location in patent: Page/Page column 212-213
[2] Tetrahedron Letters, 2009, vol. 50, # 28, p. 4030 - 4032
[3] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
[4] Chemical Communications, 2007, # 38, p. 3957 - 3959
[5] Journal of the American Chemical Society, 1990, vol. 112, # 17, p. 6248 - 6254
[6] Bulletin des Societes Chimiques Belges, 1982, vol. 91, # 2, p. 153 - 162
[7] Journal of the Chemical Society, Faraday Transactions, 1993, vol. 89, # 1, p. 43 - 48
[8] Bulletin des Societes Chimiques Belges, 1982, vol. 91, # 2, p. 153 - 162
[9] Patent: US2009/306096, 2009, A1, . Location in patent: Page/Page column 19-20
[10] Patent: WO2005/92304, 2005, A2, . Location in patent: Page/Page column 39
[11] Organic Letters, 2012, vol. 14, # 23, p. 6104 - 6107
  • 20
  • [ 6164-79-0 ]
  • [ 23688-89-3 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 21, p. 7678 - 7692
  • 21
  • [ 6164-79-0 ]
  • [ 23611-75-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 22, p. 6760 - 6766
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 21, p. 7678 - 7692
[3] Patent: US2015/18328, 2015, A1,
[4] Patent: WO2015/3640, 2015, A1,
[5] Medicinal Chemistry Research, 2015, vol. 24, # 7, p. 2986 - 2992
  • 22
  • [ 6164-79-0 ]
  • [ 27825-21-4 ]
  • [ 33332-25-1 ]
Reference: [1] Magnetic Resonance in Chemistry, 2009, vol. 47, # 7, p. 617 - 624
  • 23
  • [ 6164-79-0 ]
  • [ 20010-99-5 ]
Reference: [1] Supramolecular Chemistry, 2018, vol. 30, # 4, p. 296 - 304
  • 24
  • [ 6164-79-0 ]
  • [ 64224-21-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 12, p. 2843 - 2851
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 6164-79-0 ]

Esters

Chemical Structure| 6924-68-1

[ 6924-68-1 ]

Ethyl pyrazine-2-carboxylate

Similarity: 0.96

Chemical Structure| 13924-94-2

[ 13924-94-2 ]

Methyl 5-aminopyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 118853-60-4

[ 118853-60-4 ]

Methyl 6-aminopyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 27825-20-3

[ 27825-20-3 ]

Methyl 3-Hydroxy-2-pyrazinecarboxylate

Similarity: 0.87

Chemical Structure| 13924-95-3

[ 13924-95-3 ]

Methyl 5-hydroxypyrazine-2-carboxylate

Similarity: 0.85

Related Parent Nucleus of
[ 6164-79-0 ]

Pyrazines

Chemical Structure| 6924-68-1

[ 6924-68-1 ]

Ethyl pyrazine-2-carboxylate

Similarity: 0.96

Chemical Structure| 13924-94-2

[ 13924-94-2 ]

Methyl 5-aminopyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 118853-60-4

[ 118853-60-4 ]

Methyl 6-aminopyrazine-2-carboxylate

Similarity: 0.88

Chemical Structure| 98-97-5

[ 98-97-5 ]

Pyrazine-2-carboxylic acid

Similarity: 0.87

Chemical Structure| 27825-20-3

[ 27825-20-3 ]

Methyl 3-Hydroxy-2-pyrazinecarboxylate

Similarity: 0.87